The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The BCG Experience: Implications for Future Vaccines against Tuberculosis
Abstract
Use of BCG (bacille Calmette-Guerin) vaccines increased in Europe after World War II and in developing countries starting in the 1950s to the extent that the vaccines have now been given to over 3 billion people. In a major evaluation of BCG's safety, researchers attempted to catalog all adverse events reported as attributed to BCG vaccination. Two conclusions are notable. First, the reports of severe neurologic or fatal sequelae indicate that the risk of such events is extremely rare, far less than that reported for the smallpox vaccine. Second, BCG vaccines are associated with a variety of more common minor adverse effects in addition to induration and ulceration of the vaccination site, which occur in almost all vaccines. The authors believe that such studies may identify useful surrogate markers for the evaluation of different preparations of BCG or new vaccines against tuberculosis. Although BCG is effective in developing type I CD4 T-cell responses, it is still unclear how effective it is in generating MHC class I-restricted CTL responses. It may ultimately be necessary to identify the molecules, either enzymes or lysins, that enable M. tuberculosis to escape from phagolysosomes into the cytoplasm in order to develop recombinant BCG vaccines that are effective in inducing both CD8- and CD4-type protective responses. Just as the BCG trials have provided our most detailed studies of the epidemiology of tuberculosis, so basic research directed at tuberculosis vaccines is leading the way in understanding pathogenesis of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg
Vidal, S. M., Malo, D., Vogan, K., Skamene, E., & Gros, P. (1993) · Cell · doi:10.1016/0092-8674(93)90135-d · Cited by 1,104
Cited by
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Variation in protection by BCG: implications of and for heterologous immunity
Fine, P. E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92348-9 · Cited by 1,380
Self-citationPym, A. S., Brodin, P., Brosch, R., Huerre, M., & Cole, S. T. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03237.x · Cited by 729
“The fact that BCG has never reverted to virulence (Bloom and Fine, 1994; Mahairas et al., 1996; Oettinger et al., 1999) is consistent with the notion that the RD1 deletion represents one of several steps to avirulence in this species and explains why BCG has been such a safe vaccine in the…”
BackgroundType 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 666
Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette‐Guérin Attenuation
Lewis, K. N., Liao, R., Guinn, K. M., Hickey, M. J., Smith, S., Behr, M. A., & Sherman, D. R. (2003) · The Journal of Infectious Diseases · doi:10.1086/345862 · Cited by 588
Metadata
- Authors
- Bloom, B. R., & Fine, P. E. M.
- Venue
- Tuberculosis
- Publisher
- ASM Press
- Published
- 2014-04-08
- Pages
- 531-557
- ISSN
- 1472-9792 (ISSN-L)
- OpenAlex
- W597644419
- Cited by
- 220
- References
- 1
- FWCI
- 24.62
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.